Half of pts with macular degeneration have ↓ effect
By | translator Choi HeeYoung
22.09.21 11:35:06
Expecting a new treatment
600 domestic patients who have received existing anti-VEGF treatment are conducting a real world study
In 58% of patients, retinal exudate remains even after one year of treatment, resulting in poor vision improvement
Researchers expect the new VEGF inhibitor Beovu to address unmet demand. Patients with neovascular age-related macular degeneration in Korea had more than half of retinal exudates at the time of one year of treatment, indicating that the vision improvement effect was not significant. It was found in PROOF, which evaluated the retinal exudate regulation effect of the first year of existing VEGF inhibitor treatment in age-related macular degeneration patients. The results of the PROOF study, in which 12 domestic ophthalmic medical staff, including Kim Jae-hwi, a specialist at Kim's eye clinc, participated as the author, were published in the Scientific Reports on August 19.
According to the study, more th
(same@dailypharm.com)
